ACADIA PHARMACEUTICALS INC (ACAD) Fundamental Analysis & Valuation

NASDAQ:ACAD • US0042251084

Current stock price

22.38 USD
+0.42 (+1.91%)
Last:

This ACAD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. ACAD Profitability Analysis

1.1 Basic Checks

  • ACAD had positive earnings in the past year.
  • In the past year ACAD had a positive cash flow from operations.
  • In the past 5 years ACAD reported 4 times negative net income.
  • ACAD had negative operating cash flow in 4 of the past 5 years.
ACAD Yearly Net Income VS EBIT VS OCF VS FCFACAD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M

1.2 Ratios

  • ACAD has a better Return On Assets (25.00%) than 96.89% of its industry peers.
  • Looking at the Return On Equity, with a value of 31.86%, ACAD belongs to the top of the industry, outperforming 96.70% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 6.43%, ACAD belongs to the best of the industry, outperforming 91.46% of the companies in the same industry.
Industry RankSector Rank
ROA 25%
ROE 31.86%
ROIC 6.43%
ROA(3y)-2.12%
ROA(5y)-7.86%
ROE(3y)0.06%
ROE(5y)-7.96%
ROIC(3y)N/A
ROIC(5y)N/A
ACAD Yearly ROA, ROE, ROICACAD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40 -60 -80

1.3 Margins

  • ACAD's Profit Margin of 36.49% is amongst the best of the industry. ACAD outperforms 96.70% of its industry peers.
  • ACAD's Profit Margin has declined in the last couple of years.
  • ACAD's Operating Margin of 9.78% is amongst the best of the industry. ACAD outperforms 90.10% of its industry peers.
  • ACAD's Operating Margin has declined in the last couple of years.
  • ACAD's Gross Margin of 91.69% is amongst the best of the industry. ACAD outperforms 92.82% of its industry peers.
  • ACAD's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 9.78%
PM (TTM) 36.49%
GM 91.69%
OM growth 3Y-58.8%
OM growth 5YN/A
PM growth 3Y-26.93%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-0.78%
ACAD Yearly Profit, Operating, Gross MarginsACAD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K -40K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. ACAD Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ACAD is destroying value.
  • Compared to 1 year ago, ACAD has less shares outstanding
  • ACAD has more shares outstanding than it did 5 years ago.
  • ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ACAD Yearly Shares OutstandingACAD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
ACAD Yearly Total Debt VS Total AssetsACAD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • ACAD has an Altman-Z score of 6.55. This indicates that ACAD is financially healthy and has little risk of bankruptcy at the moment.
  • ACAD's Altman-Z score of 6.55 is fine compared to the rest of the industry. ACAD outperforms 75.34% of its industry peers.
  • There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 6.55
ROIC/WACC0.68
WACC9.41%
ACAD Yearly LT Debt VS Equity VS FCFACAD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

2.3 Liquidity

  • A Current Ratio of 3.83 indicates that ACAD has no problem at all paying its short term obligations.
  • ACAD has a Current ratio (3.83) which is comparable to the rest of the industry.
  • A Quick Ratio of 3.71 indicates that ACAD has no problem at all paying its short term obligations.
  • ACAD has a Quick ratio (3.71) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.83
Quick Ratio 3.71
ACAD Yearly Current Assets VS Current LiabilitesACAD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ACAD Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 377.08% over the past year.
  • ACAD shows a strong growth in Revenue. In the last year, the Revenue has grown by 113.98%.
  • The Revenue has been growing by 19.39% on average over the past years. This is quite good.
EPS 1Y (TTM)377.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8100%
Revenue 1Y (TTM)113.98%
Revenue growth 3YN/A
Revenue growth 5Y19.39%
Sales Q2Q%9.39%

3.2 Future

  • ACAD is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.73% yearly.
  • The Revenue is expected to grow by 11.23% on average over the next years. This is quite good.
EPS Next Y-78.31%
EPS Next 2Y-34.05%
EPS Next 3Y-9.81%
EPS Next 5Y7.73%
Revenue Next Year15.52%
Revenue Next 2Y13.59%
Revenue Next 3Y13.33%
Revenue Next 5Y11.23%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ACAD Yearly Revenue VS EstimatesACAD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 500M 1B 1.5B 2B
ACAD Yearly EPS VS EstimatesACAD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

6

4. ACAD Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 9.77, the valuation of ACAD can be described as very reasonable.
  • Based on the Price/Earnings ratio, ACAD is valued cheaper than 96.70% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.42, ACAD is valued rather cheaply.
  • ACAD is valuated quite expensively with a Price/Forward Earnings ratio of 45.07.
  • Based on the Price/Forward Earnings ratio, ACAD is valued cheaply inside the industry as 90.68% of the companies are valued more expensively.
  • ACAD is valuated expensively when we compare the Price/Forward Earnings ratio to 22.29, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 9.77
Fwd PE 45.07
ACAD Price Earnings VS Forward Price EarningsACAD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ACAD is valued cheaper than 94.56% of the companies in the same industry.
  • 88.74% of the companies in the same industry are more expensive than ACAD, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 604.88
EV/EBITDA 14.07
ACAD Per share dataACAD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • ACAD has a very decent profitability rating, which may justify a higher PE ratio.
  • ACAD's earnings are expected to decrease with -9.81% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-34.05%
EPS Next 3Y-9.81%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ACAD Dividend Analysis

5.1 Amount

  • No dividends for ACAD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ACAD Fundamentals: All Metrics, Ratios and Statistics

ACADIA PHARMACEUTICALS INC

NASDAQ:ACAD (4/27/2026, 9:48:53 AM)

22.38

+0.42 (+1.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-06
Inst Owners98.69%
Inst Owner Change0.49%
Ins Owners0.28%
Ins Owner Change1.82%
Market Cap3.82B
Revenue(TTM)1.07B
Net Income(TTM)391.00M
Analysts80
Price Target32.37 (44.64%)
Short Float %6.33%
Short Ratio5.91
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)611.18%
Min EPS beat(2)178.22%
Max EPS beat(2)1044.15%
EPS beat(4)3
Avg EPS beat(4)308.41%
Min EPS beat(4)-3.19%
Max EPS beat(4)1044.15%
EPS beat(8)6
Avg EPS beat(8)160.73%
EPS beat(12)8
Avg EPS beat(12)114.4%
EPS beat(16)11
Avg EPS beat(16)90.18%
Revenue beat(2)0
Avg Revenue beat(2)-3.01%
Min Revenue beat(2)-4.84%
Max Revenue beat(2)-1.19%
Revenue beat(4)1
Avg Revenue beat(4)-1.72%
Min Revenue beat(4)-4.84%
Max Revenue beat(4)0.08%
Revenue beat(8)2
Avg Revenue beat(8)-2.38%
Revenue beat(12)5
Avg Revenue beat(12)-0.75%
Revenue beat(16)6
Avg Revenue beat(16)-1.42%
PT rev (1m)0.67%
PT rev (3m)4.87%
EPS NQ rev (1m)-7.16%
EPS NQ rev (3m)-44.09%
EPS NY rev (1m)-1.82%
EPS NY rev (3m)-38.46%
Revenue NQ rev (1m)-0.56%
Revenue NQ rev (3m)-0.43%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)3.24%
Valuation
Industry RankSector Rank
PE 9.77
Fwd PE 45.07
P/S 3.56
P/FCF 604.88
P/OCF 34.74
P/B 3.11
P/tB 3.41
EV/EBITDA 14.07
EPS(TTM)2.29
EY10.23%
EPS(NY)0.5
Fwd EY2.22%
FCF(TTM)0.04
FCFY0.17%
OCF(TTM)0.64
OCFY2.88%
SpS6.28
BVpS7.2
TBVpS6.56
PEG (NY)N/A
PEG (5Y)N/A
Graham Number19.2598 (-13.94%)
Profitability
Industry RankSector Rank
ROA 25%
ROE 31.86%
ROCE 8.14%
ROIC 6.43%
ROICexc N/A
ROICexgc N/A
OM 9.78%
PM (TTM) 36.49%
GM 91.69%
FCFM 0.59%
ROA(3y)-2.12%
ROA(5y)-7.86%
ROE(3y)0.06%
ROE(5y)-7.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-58.8%
OM growth 5YN/A
PM growth 3Y-26.93%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-0.78%
F-Score3
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 880.34%
Cap/Sales 9.66%
Interest Coverage 250
Cash Conversion 94.22%
Profit Quality 1.61%
Current Ratio 3.83
Quick Ratio 3.71
Altman-Z 6.55
F-Score3
WACC9.41%
ROIC/WACC0.68
Cap/Depr(3y)535%
Cap/Depr(5y)327.69%
Cap/Sales(3y)570.92%
Cap/Sales(5y)342.6%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)377.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8100%
EPS Next Y-78.31%
EPS Next 2Y-34.05%
EPS Next 3Y-9.81%
EPS Next 5Y7.73%
Revenue 1Y (TTM)113.98%
Revenue growth 3YN/A
Revenue growth 5Y19.39%
Sales Q2Q%9.39%
Revenue Next Year15.52%
Revenue Next 2Y13.59%
Revenue Next 3Y13.33%
Revenue Next 5Y11.23%
EBIT growth 1Y201.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.58%
EBIT Next 3Y52.42%
EBIT Next 5Y44.2%
FCF growth 1Y549.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y7923.08%
OCF growth 3YN/A
OCF growth 5YN/A

ACADIA PHARMACEUTICALS INC / ACAD Fundamental Analysis FAQ

What is the fundamental rating for ACAD stock?

ChartMill assigns a fundamental rating of 6 / 10 to ACAD.


What is the valuation status of ACADIA PHARMACEUTICALS INC (ACAD) stock?

ChartMill assigns a valuation rating of 6 / 10 to ACADIA PHARMACEUTICALS INC (ACAD). This can be considered as Fairly Valued.


What is the profitability of ACAD stock?

ACADIA PHARMACEUTICALS INC (ACAD) has a profitability rating of 6 / 10.


Can you provide the financial health for ACAD stock?

The financial health rating of ACADIA PHARMACEUTICALS INC (ACAD) is 8 / 10.